Vedolizumab treatment persistence and safety in a 2‐year data analysis of an extended access programme

BACKGROUND: Vedolizumab was shown to be effective and safe for patients with ulcerative colitis (UC) or Crohn's disease (CD) in the GEMINI phase 3 and long‐term safety (LTS) studies. AIM: To report treatment persistence and safety results up to 2 years after enrolment in the vedolizumab extende...

Descripción completa

Detalles Bibliográficos
Autores principales: Danese, Silvio, Subramaniam, Kavitha, Van Zyl, Jan, Adsul, Shashi, Lindner, Dirk, Roth, Jeannine, Vermeire, Séverine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Vedolizumab Safety and Persistence over 2 Years
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839669/
https://www.ncbi.nlm.nih.gov/pubmed/33210333
http://dx.doi.org/10.1111/apt.16160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839669/
https://www.ncbi.nlm.nih.gov/pubmed/33210333
http://dx.doi.org/10.1111/apt.16160

Ejemplares similares